Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 November 2017Website:
http://sperotherapeutics.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 64 min agoDividend
Analysts recommendations
Institutional Ownership
SPRO Latest News
Spero Therapeutics, Inc. (Nasdaq: SPRO) will be represented by its President and CEO, Sath Shukla, at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ in New York on May 20, 2024. Shukla will participate in a fireside chat and be available for one-on-one meetings.
Spero Therapeutics, Inc. (SPRO) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of a loss of $0.18 per share. This compares to earnings of $0.55 per share a year ago.
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 44th Annual Healthcare Conference, which is taking place March 4-6, 2024, at the Boston Marriott Copley Place in Boston, MA. Details are as follows:
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations and Strategic Finance Sath Shukla - Chief Executive Officer Kamal Hamed - Chief Medical Officer Steve Dipalma - Interim Chief Financial Officer and Treasurer Conference Call Participants Louise Chen - Cantor Fitzgerald Boobalan Pachaiyappan - H.C. Wainwright Good afternoon and welcome to the Spero Therapeutics Third Quarter 2023 Financial Results Conference Call.
Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The heavy selling pressure might have exhausted for Spero Therapeutics, Inc. (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.87 per share a year ago.
Spero Therapeutics shares soared after the clinical-stage biopharmaceutical company announced that it has received special protocol approval from the United States Food and Drug Administration (FDA) for the design and size of its Phase 3 study of its investigational therapeutic tebipenem HBr in patients with complicated urinary tract infection (cUTI), including acute pyelonephritis (AP). Shares of the Cambridge, Massachusetts-based company, which is focused on developing and commercializing treatments for rare diseases and multi-drug resistant bacterial infections, had added 14.1% at US$1.62 on Monday afternoon.
What type of business is Spero Therapeutics?
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
What sector is Spero Therapeutics in?
Spero Therapeutics is in the Healthcare sector
What industry is Spero Therapeutics in?
Spero Therapeutics is in the Biotechnology industry
What country is Spero Therapeutics from?
Spero Therapeutics is headquartered in United States
When did Spero Therapeutics go public?
Spero Therapeutics initial public offering (IPO) was on 02 November 2017
What is Spero Therapeutics website?
https://sperotherapeutics.com
Is Spero Therapeutics in the S&P 500?
No, Spero Therapeutics is not included in the S&P 500 index
Is Spero Therapeutics in the NASDAQ 100?
No, Spero Therapeutics is not included in the NASDAQ 100 index
Is Spero Therapeutics in the Dow Jones?
No, Spero Therapeutics is not included in the Dow Jones index
When does Spero Therapeutics report earnings?
The next expected earnings date for Spero Therapeutics is 09 August 2024